Supplementary




Figure S1. Diagram of the study.




Figure S2. Subgroup analyses of progression-free survival. Subgroup analysis were presented from a Cox proportional-hazards model.

	NO.of	ICI	ICI	•	Hazard Ratio
Subgroup	Patients	monotherapy	plus Nab-Paclitaxel		(95%CI)
Overall	55	38	17		0.42 (0.20-0.89)
Sex					
Male	43	29	14		0.41 (0.18-0.92)
Famle	12	9	3		0.68 (0.08-5.62)
Age					
<65 yr	46	32	14	-	0.34 (0.15-0.79)
≥65 yr	9	6	3		1.32 (0.24-7.29)
Smoking status					, ,
Current or Former	29	19	10		0.58 (0.24-1.42)
Never	25	18	7		0.19 (0.04-0.85)
Unknown	1	1	0		,
KPS					
90	34	24	10	-	0.33 (0.11-0.99)
80-70	21	14	7		0.34 (0.11-1.08)
Histologic type					,
Squamous	16	12	4		0.30 (0.07-1.39)
Adenocarcinoma	39	26	13	-	0.47 (0.20-1.15)
Brain metastasis at baseline					,
YES	17	10	7		0.45 (0.14-1.49)
NO	38	28	10		0.41 (0.15-1.08)
Liver metastasis at baseline					(/
YES	9	7	2 -		— 0.02 (0.00-18.87)
NO	46	31	15		0.53 (0.24-1.14)
Bone metastasis at baseline					,
YES	17	13	4	+-	- 2.59 (0.71-9.48)
NO	38	25	13		0.28 (0.10-0.75)
Previous EGFR TKI					,
YES	19	14	5		0.52 (0.11-2.37)
NO	36	24	12		0.39 (0.16-0.94)
Number of previous systemic treatments					(,
1	20	14	6		0.57 (0.16-2.05)
≥2	35	24	11		0.38 (0.15-0.96)
				0.1 1	10
				4 0.1 1 − 1	
		Fa	vors ICI plus Nab-paclita	axel Fa	avors ICI monotherapy

Figure S3. Subgroup analyses of overall survival. Subgroup analysis were presented from a Cox proportional-hazards model.




Figure S4. Waterfall plots of best percentage change. (A) The best percentage change from baseline in tumor size for patients who received anti-PD-1/PD-L1 monotherapy. (B) The best percentage change from baseline in tumor size for patients who received anti-PD-1/PD-L1 plus nab-paclitaxel.